Archived News Releases


2016 | 2015 | 2014 | 2013 | 2012 | 2011
Keyword Search
 
DateTitle 
11/26/13ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Nov. 26, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: The Piper Jaffray 25th Annual Healthcare Conference on Tuesday, December 3, 2013, at 10:00 a.m. Eastern Time in New York City. The Oppenheimer 24th Annual Healthcare Conferen... 
Printer Friendly Version
11/14/13ACADIA Pharmaceuticals Announces Initiation of Phase II Trial with Pimavanserin for Alzheimer’s Disease Psychosis
SAN DIEGO--(BUSINESS WIRE)--Nov. 14, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer’s disease psychosis (ADP). No drug is approve... 
Printer Friendly Version
11/06/13ACADIA Pharmaceuticals Reports Third Quarter 2013 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Nov. 6, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the third quarter ended September 30, 2013. ACADIA reported a net loss of $10.7 million, or $0.12 per common share, for the third quarter of 2013 com... 
Printer Friendly Version
10/31/13ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson’s Disease Psychosis Trial with Pimavanserin
SAN DIEGO--(BUSINESS WIRE)--Oct. 31, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the publication of data from its pivotal Phase III -020 Study with pimavanserin in patients with Parkinson’s disease psychosis (PDP) in the November 1, 2013 online issue of The Lancet. In the -020 ... 
Printer Friendly Version
10/30/13ACADIA Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 6, 2013
ACADIA to Host Conference Call and Webcast on Wednesday, November 6, 2013, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Oct. 30, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended Septem... 
Printer Friendly Version
09/03/13ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Sep. 3, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences: The Morgan Stanley Global Healthcare Conference on Monday, September 9, 2013, at 9:25 a.m. Eastern Time in New York Cit... 
Printer Friendly Version
08/19/13ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer
SAN DIEGO--(BUSINESS WIRE)--Aug. 19, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced the appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer, effective today. Mr. Moore reports to ACADIA’s Chief Executive Officer, Uli Hacksell, Ph.D., and will be respons... 
Printer Friendly Version
08/06/13ACADIA Pharmaceuticals Reports Second Quarter 2013 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Aug. 6, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the second quarter ended June 30, 2013. ACADIA reported a net loss of $9.1 million, or $0.11 per common share, for the second quarter of 2013 compar... 
Printer Friendly Version
07/30/13ACADIA Pharmaceuticals to Announce Second Quarter 2013 Financial Results on August 6, 2013
ACADIA to Host Conference Call and Webcast on Tuesday, August 6, 2013, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Jul. 30, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, ... 
Printer Friendly Version
07/02/13ACADIA Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference on July 9, 2013
SAN DIEGO--(BUSINESS WIRE)--Jul. 2, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 8th Annual JMP Securities Healthcare Conference on Tuesday, July 9, 2013, at 1:00 p.m. Eastern Time at The St. Regis New York in New York City. A live webca... 
Printer Friendly Version
07/01/13ACADIA Pharmaceuticals Added to Russell 2000 Index
SAN DIEGO--(BUSINESS WIRE)--Jul. 1, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has been added to the Russell 2000 Index effective after the close of market on Friday, June 28, 2013, as part of Russell Investments’ annual index reconstitution. ACADIA also was added to th... 
Printer Friendly Version
06/18/13ACADIA Pharmaceuticals Announces Multiple Presentations of Data from Phase III Pimavanserin Program at the 17th International Congress of Parkinson’s Disease and Movement Disorders
SAN DIEGO--(BUSINESS WIRE)--Jun. 18, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, presented data today from its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), including data from its pivotal -020 Study and the related, open-label safety extension study, at a poster ... 
Printer Friendly Version
06/03/13ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical Development
SAN DIEGO--(BUSINESS WIRE)--Jun. 3, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that Allergan, Inc. (NYSE: AGN) has advanced an additional product candidate as a potential new treatment for glaucoma. The novel small molecule resulted from joint research conducted by the companie... 
Printer Friendly Version
05/29/13ACADIA Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 5, 2013
SAN DIEGO--(BUSINESS WIRE)--May 29, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2013, at 10:30 a.m. Eastern Time at the Grand Hyatt New York in New York City. A live webcast of ACADIA’s presentation will be accessible on the compa... 
Printer Friendly Version
05/20/13ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--May 20, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the completion of an underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the full exercise of an option to purchase additional shares previously granted to the underwriters. All of the shares were offered by ACADIA at a price to the public of $12.50 per share. The gross proceeds from this offering to ACADIA were $115 million, before d... 
Printer Friendly Version
05/20/13ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index
SAN DIEGO--(BUSINESS WIRE)--May 20, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: ^NBI) effective prior to today’s market open. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are cla... 
Printer Friendly Version
05/15/13ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--May 15, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock, offered at a price to the public of $12.50 per share. The gross proceeds from this offering to ACADIA are expected to be $100 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day option to purchas... 
Printer Friendly Version
05/14/13ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--May 14, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC and Cowen and Company, LLC are acting as the joint book-running managers for the offering. JMP Securities LLC and ... 
Printer Friendly Version
05/07/13ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May 7, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2013. ACADIA reported a net loss of $6.1 million, or $0.08 per common share, for the first quarter of 2013 compared to a net loss of $6.2 million, or $0.12 per common shar... 
Printer Friendly Version
04/30/13ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013
ACADIA to Host Conference Call and Webcast on Tuesday, May 7, 2013, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Apr. 30, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 201... 
Printer Friendly Version
04/25/13ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013
SAN DIEGO--(BUSINESS WIRE)--Apr. 25, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013, at 8:00 a.m. Eastern Time at The Westin New York Grand Central Hotel in New York City. ... 
Printer Friendly Version
04/11/13ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA
Single Pivotal Phase III -020 Study and Other Supportive Data Sufficient for Future NDA Filing for the Treatment of Parkinson’s Disease Psychosis Conference Call and Webcast to Be Held Today, April 11, 2013, at 8:00 am Eastern Time SAN DIEGO--(BUSINESS WIRE)--Apr. 11, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurolo... 
Printer Friendly Version
03/20/13ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Mar. 20, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou Ruvo Center for Brain Health, presented detailed results today from ACADIA’s pivotal Phase III -020 Study with pimavanserin in pati... 
Printer Friendly Version
03/13/13ACADIA Pharmaceuticals to Present at the 25th Annual ROTH Conference on March 19, 2013
SAN DIEGO--(BUSINESS WIRE)--Mar. 13, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 25th Annual ROTH Conference on Tuesday, March 19, 2013, at 10:00 a.m. Pacific Time at The Ritz-Carlton in Laguna Niguel. A live webcast of ACADIA's presentation will be accessible on the company's website, www.... 
Printer Friendly Version
03/12/13ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
SAN DIEGO--(BUSINESS WIRE)--Mar. 12, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2012. ACADIA reported a net loss of $6.8 million, or $0.11 per common share, for the fourth quarter of 201... 
Printer Friendly Version
03/05/13ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013
ACADIA to Host Conference Call and Webcast on Tuesday, March 12, 2013, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Mar. 5, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year e... 
Printer Friendly Version
02/25/13ACADIA Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013
SAN DIEGO--(BUSINESS WIRE)--Feb. 25, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Cowen and Company 33rd Annual Health Care Conference on Monday, March 4, 2013, at 1:30 p.m. Eastern Time at the Boston Marriott Copley Place. A live we... 
Printer Friendly Version
02/05/13ACADIA Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference on February 12, 2013
SAN DIEGO--(BUSINESS WIRE)--Feb. 5, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it will present at the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013, at 10:00 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. A live ... 
Printer Friendly Version
01/22/13ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Jan. 22, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the election of Stephen R. Biggar, M.D., Ph.D., to its board of directors. Dr. Biggar will fill a vacancy on ACADIA’s board and serve as a Class II director. The terms of the Class II directors ... 
Printer Friendly Version